About Evommune, Inc.
https://www.evommune.comEvommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
CEO
Luis C. Pena
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 6, 2025
Full time employees 45
ETFs Holding This Stock
Summary
Total 18
Showing Top 3 of 18
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $42
Target Low $35
Target Median $40
Target Consensus $38.6
Market Cap $234.64 M
52w High $24.03
52w Low $13.88
P/E -10.02
Volume 520.65K
Outstanding Shares 12.87M
About Evommune, Inc.
https://www.evommune.comEvommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $10M ▲ | $23.02M ▲ | $-12.47M ▲ | -124.75% ▼ | $-0.4 ▲ | $-12.16M ▲ |
| Q2-2025 | $0 ▼ | $22.62M ▲ | $-13.56M ▲ | 0% ▲ | $-0.45 ▲ | $-13.19M ▲ |
| Q1-2025 | $3M ▲ | $17.66M ▼ | $-14.56M ▲ | -485.23% ▼ | $-0.48 ▲ | $-14.18M ▲ |
| Q2-2024 | $0 ▼ | $27.96M ▲ | $-27.38M ▼ | 0% ▲ | $-0.91 ▼ | $-27.05M ▼ |
| Q1-2024 | $7M | $10.48M | $-2.78M | -39.77% | $-0.09 | $-2.5M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $76.06M ▼ | $84.54M ▼ | $267.68M ▲ | $-183.14M ▼ |
| Q2-2025 | $86.8M ▲ | $96.21M ▲ | $267.44M ▲ | $-171.23M ▼ |
| Q1-2025 | $48.41M | $56.02M | $214.25M | $-158.24M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.47M ▲ | $-9.63M ▲ | $-23.91M ▼ | $-274K ▼ | $-35.02M ▼ | $-9.77M ▲ |
| Q2-2025 | $-13.56M ▲ | $-26.21M ▼ | $18M ▲ | $64.34M ▲ | $56.13M ▲ | $-26.21M ▼ |
| Q1-2025 | $-14.56M ▲ | $-23.9M ▼ | $13.5M ▲ | $-152K ▼ | $5.7M ▲ | $-23.9M ▼ |
| Q2-2024 | $-27.38M ▼ | $-8.63M ▼ | $10.03M ▲ | $-108K ▼ | $0 | $-8.64M ▼ |
| Q1-2024 | $-2.78M | $-4.83M | $9.65M | $-60K | $0 | $-4.9M |
CEO
Luis C. Pena
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 6, 2025
Full time employees 45
ETFs Holding This Stock
Summary
Total 18
Showing Top 3 of 18
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $42
Target Low $35
Target Median $40
Target Consensus $38.6